Toxicity Summary
IDENTIFICATION AND USE: Diammonium L-(+)-tartrate forms crystals or white granules. It is used in the textile industry. It is also suitable for clinical dosimetry using electron spin resonance (ESR). HUMAN STUDIES: Use of a 10% solution at pH 7 on patients' eyes following chemical burns seems to have caused no recognized additional injury, but the treatment is painful, especially if solution has decomposed and is no longer neutral. ANIMAL STUDIES: A 10% solution is not completely innocuous. Such a solution at pH 7 applied continuously for 30 minutes to a rabbit's eye after mechanical removal of epithelium caused no permanent damage, but did cause edema of the cornea lasting several days.

---

Non-Human Toxicity Values
LD50 Rabbit iv 113 mg/kg
LD50 Rabbit sc 1130 mg/kg

[1]. Growth, molecular structure, NBO analysis and vibrational spectral analysis of l-tartaric acid single crystal. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 5;123:127-41.

[2]. L-tartaric acid synthesis from vitamin C in higher plants. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5608-13.

[3]. L-Tartaric Acid Exhibits Antihypertensive and Vasorelaxant Effects: The Possible Role of eNOS/NO/cGMP Pathways. Cardiovasc Hematol Agents Med Chem. 2023;21(3):202-212.

[4]. Re-evaluation of l(+)-tartaric acid (E 334), sodium tartrates (E 335), potassium tartrates (E 336), potassium sodium tartrate (E 337) and calcium tartrate (E 354) as food additives. EFSA J. 2020 Mar 11;18(3):e06030.

Ammonium tartrate is a white crystalline solid. It is soluble in water. The primary hazard is the threat to the environment. Immediate steps should be taken to limit its spread to the environment. It is used to manufacture fabrics and in medicine.

---

Therapeutic Uses
/EXPL THER/ This study is one step in the search for an ESR dosimeter material with a higher signal intensity than the commonly used l-a-alanine, to be useful in the clinical dose range (approximately 0.1-20 Gy). The substance ammonium tartrate was found and investigated regarding signal intensity, radical stability, dose response and dose resolution. The ESR signal intensity of ammonium tartrate was shown to be more than twice the intensity of the alanine signal. The data indicate that an unstable radiation induced radical contributes to the ESR signal initially; after a couple of hours it has converted to a secondary radical which has a decay slow enough to be considered stable during the first two weeks after irradiation. Ammonium tartrate has a linear dose response in the investigated range of 0.5-4000 Gy and a dose resolution of 0.1 Gy at the 0.5 Gy level where, as a comparison, the corresponding value for alanine is 0.3 Gy. We thus find the substance suitable for clinical dosimetry.
/EXPL THER/ The crystalline substance ammonium tartrate is investigated with respect to its suitability as a clinical dosimetry material. The properties investigated are: the radical stability for absorbed doses relevant for clinical use, the improvement in sensitivity when the crystals are deuterated and the linear electron transfer (LET)-dependence. After photon irradiation to an absorbed dose of 20 Gy, the signal increases rapidly during the first 6 hr. After this period, the changes are more moderate and can be corrected for. The signal-to-noise ratio of irradiated ammonium tartrate is twice the corresponding value of alanine. By deuterating the crystals, the sensitivity can be further improved by a factor of 1.4. As expected, the signal decreases with increasing LET of the radiation, but no changes in the spectrum shape was observed.
/EXPL THER/ This paper continues analyses on organic compounds for application in neutron dosimetry performed through electron spin resonance (ESR). Here, the authors present the results obtained by ESR measurements of a blend of ammonium tartrate dosemeters and gadolinium oxide (5% by weight). The choice of low amount of Gd is due to the need of improving neutron sensitivity while not significantly influencing tissue equivalence. A study of the effect of gadolinium presence on tissue equivalence was carried out. The experiments show that the neutron sensitivity is enhanced by more than an order of magnitude even with this small additive content. Monte Carlo simulations on the increment of energy release due to gadolinium presence were carried, and the results were in good agreement with the experimental data.
/EXPL THER/ Use of /a 10% solution of ammonium tartrate at pH 7/ on patients' eyes following chemical burns seems to have caused no recognized additional injury, but the treatment is painful, especially if solution has decomposed and is no longer neutral.
Solutions of ammonium tartrate, as well as solutions of other ammonium salts, dissolve certain metal salts which are poorly soluble in water by forming complexes with them. The solubilizing action of ammonium tartrate on calcium carbonate, lead carbonate, and copper precipitates has been exploited for dissolving incrustations of these compounds from the cornea of enucleated pig eyes, living rabbit eyes, and eyes of patients. Many observations have been published on the use of this treatment, in many instances applied indiscriminately and illogically where no metal incrustations existed. The rational basis for use of complexing ammonium salts such as ammonium tartrate to solubilize deposits of lime and other metals in the cornea apparently was forgotten during the half century after the introduction of this treatment, and an unfortunate custom developed of treating all sorts of alkali burns of the eye with neutral ammonium tartrate solution, with no evidence that this was of any value, except possibly in removing deposits of lime (calcific deposits). A careful evaluation of neutral ammonium tartrate solution in treatment of sodium hydroxide burns has been carried out ... on the eyes of rabbits, and has established clearly that this old treatment did not accomplish any better removal of alkali from the tissues than irrigation with water, and did not have any better influence on the clinical course or final results of the injury.

C4H12N2O6

184.15

184.069

3164-29-2

L-Tartaric acid;87-69-4

2724224

Colorless, crystalline (sand-like) solid or white granule
White crystals
Crystals or white granules

1.601 g/mL at 25 °C(lit.)

399.3ºC at 760mmHg

209.4ºC

120.72

4

6

1

12

123

0

C(C(C(=O)O)O)(C(=O)O)O.N.N

NGPGDYLVALNKEG-UHFFFAOYSA-N

InChI=1S/C4H6O6.2H3N/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);2*1H3

diazanium;2,3-dihydroxybutanedioate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。